Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture

Vox Sanguinis

Volumn 104, Issue 1, 2013, Pages 19-29

  Muller M M ^a   Fraile, M I G ^b   Hourfar, M K ^a   Peris, L B ^b   Sireis, W ^a   Rubin, M G ^b   Lopez E M ^b   Rodriguez, G T ^b   Seifried, E ^a   Saldanha, J ^c   Schmidt, M ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Centro de Hemoterapia Y Hemodonacion de Castilla Y Leon   (Spain)

^c ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

Blood screening; Multi dye; NAT test; Plasma screening

Indexed keywords

ARTICLE; BLOOD ANALYSIS; BLOOD BANK; CONTROLLED STUDY; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN PARVOVIRUS B19; HUMAN TISSUE; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; VIRUS DETECTION;

BLOOD BANKS; BLOOD DONORS; BLOOD SAFETY; EUROPE; GENOTYPE; HEPACIVIRUS; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MASS SCREENING; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PARVOVIRUS B19, HUMAN; REPRODUCIBILITY OF RESULTS;

EID: 84871341607     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01635.x     Document Type: Article

References (36)

1. Roth WK, Busch MP, Schuller A, et al.: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012; 102:82-90.
2. Groner A: Pathogen safety of plasma-derived products - Haemate P/Humate-P. Haemophilia 2008; 14(Suppl 5):54-71.
3. Anonymous: Human anti-D Immunoglobulin, Monograph 0557 (Since 1/1/2004); Human Anti-D Immunoglobulin for Intravenous Administration, Monograph 1527 (Since 1/1/2004); Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646 (Since 1/7/2004). Ph.Europe, 6th edn. Strasbourg, France, Council of Europe, 2011.
4. Guidance for Industry: Nucleic Acid Testing (NAT) to Reduce the Possible Risk of Human Parvovirus B19 Transmission by Plasma-derived Products, U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. July 2009 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
5. Anonymous: Human Plasma (Pooled and Treated for Virus Inactivation), Monograph 1646 (since 01/2011). Ph.Europe, 6th edn. Strasbourg, France, Council of Europe, 2011.
6. Brojer E, Grabarczyk P, Liszewski G, et al.: Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology 2006; 44:1666-1674.
7. Servant A, Laperche S, Lallemand F, et al.: Genetic diversity within human erythroviruses: identification of three genotypes. J Virol 2002; 76:9124-9134.
8. Baylis SA, Shah N, Minor PD: Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma. J Virol Methods 2004; 121:7-16.
9. Schmidt M, Pichl L, Jork C, et al.: Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes. Vox Sang 2010; 98:37-46.
10. Kleines M, Schellenberg K, Ritter K: Efficient extraction of viral DNA and viral RNA by the Chemagic viral DNA/RNA kit allows sensitive detection of cytomegalovirus, hepatitis B virus, and hepatitis G virus by PCR. J Clin Microbiol 2003; 41:5273-5276.
11. Schmidt M, Themann A, Drexler C, et al.: Blood donor screening for parvovirus B19 in Germany and Austria. Transfusion 2007; 47:1775-1782.
12. Hourfar MK, Mayr-Wohlfart U, Themann A, et al.: Recipients potentially infected with parvovirus B19 by red blood cell products. Transfusion 2011; 51:129-136.
13. Heitmann A, Laue T, Schottstedt V, et al.: Occurrence of hepatitis A virus genotype III in Germany requires the adaptation of commercially available diagnostic test systems. Transfusion 2005; 45:1097-1105.
14. Saldanha J, Lelie N, Yu MW, et al.: Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques. Vox Sang 2002; 82:24-31.
15. Saldanha J, Heath A, Lelie N, et al.: A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays. Vox Sang 2005; 89:52-58.
16. Roth WK, Weber M, Buhr S, et al.: Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002; 42:862-868.
17. Roth WK, Seifried E: The German experience with NAT. Transfus Med 2002; 12:255-258.
18. Seifried E, Findhammer S, Roth WK: Status of NAT screening for HCV, HIV and HBV - experiences of the German Red Cross Blood Donation Services. Dev Biol (Basel) 2002; 108:23-27.
19. Roth WK, Weber M, Seifried E: Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet 1999; 353:359-363.
20. Hourfar MK, Schmidt M, Seifried E, et al.: Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment. Vox Sang 2005; 89:71-76.
21. Hourfar MK, Michelsen U, Schmidt M, et al.: High-throughput purification of viral RNA based on novel aqueous chemistry for nucleic acid isolation. Clin Chem 2005; 51:1217-1222.
22. Alvarez M, Oyonarte S, Rodriguez PM, et al.: Estimated risk of transfusion-transmitted viral infections in Spain. Transfusion 2002; 42:994-998.
23. Solves P, Mirabet V, Alvarez M, et al.: Donor screening for hepatitis B virus infection in a cell and tissue bank. Transpl Infect Dis 2008; 10:391-395.
24. Gonzalez R, Torres P, Castro E, et al.: Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2010; 50:221-230.
25. Gonzalez R, Echevarria JM, Avellon A, et al.: Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain. Transfusion 2006; 46:1138-1142.
26. Li L, Chen PJ, Chen MH, et al.: A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008; 48:1198-1206.
27. Dettori S, Candido A, Kondili LA, et al.: Identification of low HBV-DNA levels by nucleic acid amplification test (NAT) in blood donors. J Infect 2009; 59:128-133.
28. ®: TaqScreen MPX Test, Version 2.0 for Use on the cobas s 201 System, Rev. 1, 01/2011. Package Insert, Roche Molecular Systems, Inc., Branchburg, NJ, USA, 2011.
29. ®: TaqScreen MPX Test, for Use on the cobas s 201 System, Rev. 5, 01/2010. Package Insert, Roche Molecular Systems, Inc., Branchburg, NJ, USA, 2010.
30. Seifried E, Rüster B, Sireis W, et al.: Zelos x100 enables detection of transfusion relevant viruses as well as bacterial detection in platelets - a new cost efficient alternative to commercial bacterial screening methods. Vox Sang 2011; 101(Suppl 2):6.
31. Gen-Probe, Incorporated: Procleix Ultrio Assay, 500939 Rev. A. Gen-Probe Incorporated, San Diego, CA, USA, 2008.
32. Assal A, Barlet V, Deschaseaux M, et al.: Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009; 49:301-310.
33. Assal A, Barlet V, Deschaseaux M, et al.: Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201. Transfusion 2009; 49:289-300.
34. Margaritis AR, Brown SM, Seed CR, et al.: Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA. Transfusion 2007; 47:1783-1793.
35. IFU cobas®: TaqScreen DPX Test for Use on the cobas s 201 System, Rev. 1, 6/2010. Package Insert, Roche Molecular Systems, Inc., Branchburg, NJ, USA, 2010.
36. Koppelman MHGM, Cuijpers HTM, Wessberg S, et al. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA. Transfusion 2012; in press (7 pp).